About utR Biotech Ltd.
utR Biotech Ltd. is a pioneering biopharmaceutical company based in Winnipeg, Manitoba, dedicated to transforming the landscape of diabetes treatment through innovative biotechnology. Founded in 2016 by David Petch, our company is driven by a bold vision: to improve the quality of life for insulin-dependent diabetics by incorporating C-peptide into insulin formulations. This groundbreaking approach has the potential to mitigate serious secondary complications of diabetes, such as cardiovascular disease, neuropathy, Alzheimer’s disease, and cancer.
At utR Biotech, we are passionate about delivering affordable, effective therapeutics designed for low- and middle-income individuals. Our cutting-edge research leverages over 23 years of industry expertise in cell culture, protein purification, and product development, setting us apart as a leader in both innovation and impact. We believe in making a difference not just for individuals, but for global health systems burdened by rising diabetes rates and associated costs.
Our Mission
utR Biotech is dedicated to delivering affordable, innovative diabetes treatments by integrating C-peptide into insulin formulations. We focus on improving patient outcomes, reducing complications, and making life-saving therapies accessible to underserved populations worldwide.
Our Vision: E4 Logic
Our vision is guided by the concept of E4 logic, where we combine Emerge, Excel, Exploit, and Evolve into a cohesive strategy. We believe that holding these four stages in a dynamic state of mind leads to exponential business and personal growth. This unique approach drives our ability to stay ahead in a competitive industry, pushing us to innovate continuously.
What We Do
utR Biotech specializes in the development, optimization, purification, and scale-up of therapeutic recombinant proteins. Our initial focus is on improving insulin formulations by adding C-peptide, which has shown potential to alleviate many diabetes-related complications. Through rigorous scientific research, we aim to develop therapies that offer superior health benefits to current products on the market. Our innovative lyophilized insulin-C-peptide formulation is designed for greater shelf-life and global accessibility, particularly benefiting underserved populations.